SQZ Biotechnologies Company (SQZ)
|Net Income (ttm)||-38.71M|
|Trading Day||January 25|
|Day's Range||24.01 - 26.00|
|52-Week Range||13.25 - 34.58|
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, ch...
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public of...
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional p... [Read more...]
|IPO Date |
Oct 30, 2020
|Stock Exchange |
|Ticker Symbol |
In 2019, SQZ's revenue was $20.11 million, an increase of 58.73% compared to the previous year's $12.67 million. Losses were -$32.20 million, 67.3% more than in 2018.
According to 4 analysts, the average rating for SQZ stock is "Strong Buy." The 12-month stock price forecast is 38.33, which is an increase of 58.13% from the latest price.